Nous-209 Vaccine: From Cancer Treatment to Interception in Lynch Syndrome Patients
Time: 9:00 am
day: Day One
Details:
- Presenting NOUS-209, an off-the-shelf cancer vaccine encoding shared neoantigens across both sporadic and hereditary Microsatellite Instable (MSI) tumours
- Showing strong immunogenicity, breadth and durability of NOUS-209 induced immune response in patients with metastatic MSI tumours and Lynch Syndrome (LS) vaccinated patients
- Highlighting NOUS-209 Potential to ‘Intercept’ Cancer in Subjects with LS
